Free tool
FAERS Monitor: Trintellix
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204447 or its brand name (Trintellix, Vortioxetine Hydrobromide). Reports on generic versions are filed under their own applications.
Reports
17,188
Serious
8,272
48% of reports
Hospitalization
2,949
Death reported
1,016
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea2,284
- fatigue1,225
- drug ineffective1,165
- headache1,075
- anxiety1,053
- vomiting1,036
- suicidal ideation969
- off label use948
- insomnia942
- dizziness904
- diarrhoea850
- pruritus806
- asthenia792
- depression786
- feeling abnormal686
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2014 | 10 |
| 2015 | 116 |
| 2016 | 1,444 |
| 2017 | 2,154 |
| 2018 | 1,866 |
| 2019 | 2,005 |
| 2020 | 1,668 |
| 2021 | 1,553 |
| 2022 | 1,419 |
| 2023 | 1,274 |
| 2024 | 1,442 |
| 2025 | 1,323 |
| 2026 | 913 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,971 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| suicidal ideationSignal | 969 | 13.1 | 12.3 | 10,732 |
| anxietySignal | 1,053 | 4.5 | 4.3 | 2,933 |
| insomniaSignal | 942 | 4.3 | 4.1 | 2,440 |
| depressionSignal | 786 | 4.2 | 4.0 | 1,956 |
| nauseaSignal | 2,284 | 3.5 | 3.4 | 4,307 |
| feeling abnormalSignal | 686 | 3.5 | 3.3 | 1,240 |
| vomitingSignal | 1,036 | 2.7 | 2.5 | 1,130 |
| astheniaSignal | 792 | 2.6 | 2.4 | 778 |
| pruritusSignal | 806 | 2.6 | 2.4 | 784 |
| dizzinessSignal | 904 | 2.2 | 2.1 | 619 |
| headacheSignal | 1,075 | 2.1 | 2.0 | 636 |
| fatigue | 1,225 | 1.9 | 1.8 | 565 |
| diarrhoea | 850 | 1.6 | 1.5 | 203 |
| off label use | 948 | 1.3 | 1.2 | 79 |
| drug ineffective | 1,165 | 1.1 | 1.0 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.